ClinConnect ClinConnect Logo
Search / Trial NCT06560398

Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)

Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Aug 15, 2024

Trial Information

Current as of August 22, 2025

Recruiting

Keywords

ClinConnect Summary

The ACT WONDER²S trial is a study aimed at improving how Black and Hispanic patients can join clinical trials for cancer treatments at the Moffitt Cancer Center. The goal is to create and evaluate different outreach and support strategies to make it easier for these communities to participate in important research that could lead to better cancer care.

To be eligible for this study, you need to live in specific areas targeted by the program, or be a doctor or research coordinator working at Moffitt. You also need to be a new patient or a newly registered existing patient at the cancer center. If you join the trial, you can expect to engage with various support activities designed to help you understand and access clinical trials. This study is currently looking for participants, so if you think you or someone you know might be eligible, it could be a great opportunity to contribute to cancer research while receiving support.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Community residents: Community residents may engage with various intervention components deployed in the intervention priority zones.
  • Community Physicians: may engage with various intervention components deployed in the intervention priority zones if they 1) practice medicine in one of the geographic priority zones.
  • Cancer Center Physicians: may engage with various intervention components if they 1) practice medicine at Moffitt.
  • Clinical Research Coordinators (CRC): may engage with various intervention components if they 1) work as a CRC at Moffitt and 2) coordinate/pre-screen patients for at least 1 therapeutic clinical trial at Moffitt.
  • Cancer Center Patients: may engage with various intervention components if they have an address that maps to an intervention priority zone and 2) are newly registered patients or new existing patients (NEPs).
  • Exclusion Criteria:
  • Community residents, Community Physicians, Cancer Center Physicians, Clinical Research Coordinators, and Moffitt patients who do not meet the inclusion criteria.

About H. Lee Moffitt Cancer Center And Research Institute

H. Lee Moffitt Cancer Center and Research Institute is a leading institution dedicated to cancer research, treatment, and education, recognized for its commitment to advancing cancer care through innovative clinical trials and groundbreaking research. As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt integrates cutting-edge science with patient-centered care, offering a multidisciplinary approach to cancer treatment. The center is at the forefront of developing novel therapies and improving outcomes for patients, emphasizing collaboration between researchers and clinicians to translate scientific discoveries into effective treatments. Through its extensive clinical trial programs, Moffitt aims to enhance the understanding of cancer biology and provide patients with access to the latest therapies and interventions.

Locations

Tampa, Florida, United States

Patients applied

0 patients applied

Trial Officials

Susan Vadaparampil, PhD

Principal Investigator

Moffitt Cancer Center

Dana Rollison, PhD

Principal Investigator

Moffitt Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported